BDTX · NASDAQ
Black Diamond Therapeutics (BDTX) Stock Price & Fundamentals
Black Diamond Therapeutics (BDTX) closed at $982.97 on Oct 9, 2026, down 0.21% from the previous close of $985.01.
Share price, past year
1Y +17.83%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $982.97 |
| Sep 30, 2026 | $968.40 |
| Aug 31, 2026 | $938.69 |
| Jul 31, 2026 | $929.58 |
| Jun 30, 2026 | $950.93 |
| May 29, 2026 | $970.09 |
| Apr 30, 2026 | $932.96 |
| Mar 31, 2026 | $923.72 |
| Feb 27, 2026 | $885.97 |
| Jan 30, 2026 | $838.69 |
| Dec 31, 2025 | $913.36 |
| Nov 28, 2025 | $888.74 |
| Oct 31, 2025 | $857.31 |
Key statistics
- Market cap
- $56.47B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.73
- Revenue (TTM)
- $0.00
- Net income (TTM)
- −$42.56M
- Shares outstanding
- 57.4M
- Dividend yield
- —
- 52-week range
- $821.21 – $996.00
Black Diamond Therapeutics's market cap is $56.47B, based on a share price of $982.97 and 57.4M shares outstanding as of Jun 30, 2026.
Financials
Black Diamond Therapeutics reported revenue of $70.00M for fiscal 2025.
Black Diamond Therapeutics earned net income of $22.37M in fiscal 2025, a net margin of 32.0%.
Fiscal 2025 revenue was the highest in the 5 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $70.00M | — | $22.37M | 32.0% | $0.39 | — |
| FY2024ended Dec 31, 2024 | $0.00 | — | −$69.68M | — | −$1.27 | −$62.30M |
| FY2020ended Dec 31, 2020 | $0.00 | — | −$67.25M | — | −$2.05 | −$52.29M |
| FY2019ended Dec 31, 2019 | $0.00 | — | −$35.26M | — | −$16.99 | −$24.70M |
| FY2018ended Dec 31, 2018 | $0.00 | — | −$8.93M | — | −$4.42 | −$8.53M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | −$9.91M | −$0.17 |
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$9.04M | −$0.16 |
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$15.12M | −$0.25 |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$8.50M | −$0.15 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$10.56M | −$0.19 |
| Q1 FY2025ended Mar 31, 2025 | $70.00M | $56.54M | $0.98 |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$15.99M | −$0.28 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$15.56M | −$0.28 |
Company profile
- Name
- Black Diamond Therapeutics, Inc.
- Ticker
- BDTX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 245 First Street, 18th Floor, Cambridge, MA 02142
- Fiscal year ends
- December
- SEC CIK
- 0001701541
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- Jun 29, 2026
- May 21, 2026
- May 7, 2026
- May 7, 2026
- Mar 16, 2026
- Mar 16, 2026
Frequently asked questions
What is Black Diamond Therapeutics's stock price?
Black Diamond Therapeutics (BDTX) closed at $982.97 on Oct 9, 2026, down 0.21% from the previous close of $985.01.
What is Black Diamond Therapeutics's market cap?
Black Diamond Therapeutics's market cap is $56.47B, based on a share price of $982.97 and 57.4M shares outstanding as of Jun 30, 2026.
How much revenue does Black Diamond Therapeutics make?
Black Diamond Therapeutics reported revenue of $70.00M for fiscal 2025.
Does Black Diamond Therapeutics pay a dividend?
Black Diamond Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Black Diamond Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures